RSV vaccination was associated with decreased risks for infection and hospitalization, although the decrease was not statistically significant.

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...

Tony Wood, GSK’s chief scientific officer, said: “We are excited by this new data which shows that a single dose of Arexvy ...

GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits ...

GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of ...

A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.